Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis

Brexucabtagene autoleucel (brexu-cel) is a chimeric antigen receptor T-cell therapy approved for relapsed/refractory mantle cell lymphoma (R/R MCL). Here, we report real-world effectiveness and safety outcomes of brexu-cel in a prospective study of patients with R/R MCL, including subgroups based on prior treatment with Bruton's tyrosine kinase inhibitor, bendamustine, or autologous hematopoietic cell transplant (auto-HCT) and number of prior therapy lines, using Center for International Blood and Marrow Transplant Research registry data. A total of 476 patients with R/R MCL who received brexu-cel between July 2020 and December 2022 were included in the analysis. With a median follow-up of 13.5 months, the overall response rate was 91% and complete response rate was 82%. One-year overall survival and progression-free survival rates were 76% and 63%, respectively. One-year cumulative incidence of nonrelapse mortality was 8%. Prior auto-HCT was associated with better duration of response within 6 months after infusion (hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.28-0.85) but greater risk of immune effector cell-associated neurotoxicity syndrome (odds ratio [OR], 1.66; 95% CI, 1.06-2.60). Prior bendamustine was associated with increased risk of prolonged thrombocytopenia (OR, 1.90; 95% CI, 1.13-3.21). In patients with 1 to 2 prior therapy lines, relapse or progression was less frequent compared with those with ≥3 prior lines (HR, 0.64; 95% CI, 0.42-1.00). Collectively, our results suggest that real-world outcomes with brexu-cel were consistent with those of the ZUMA-2 trial, regardless of prior therapy type or number of prior therapy lines.

Authors

Institutions

Publication Details

Journal
Blood Advances
Published
2025-07-24
DOI
https://doi.org/10.1182/bloodadvances.2024015014
Citations
8
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
8.36

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis

Matthew Bye, Mehdi Hamadani, Mohamed A. Kharfan‐Dabaja, Frederick Lundry Locke et al.
8 citations
Blood Advances
CAR-T cell therapy research
8.36
article

Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis

Matthew Bye, Mehdi Hamadani, Mohamed A. Kharfan‐Dabaja, Frederick Lundry Locke, Ioana Kloos, Zhen‐Huan Hu, Matthew J. Frank, Alex Francisco Herrera, Craig S. Sauter, Sairah Ahmed, Peiman Hematti, James N. Gerson, Mazyar Shadman, Natalie Sophia Grover, Lihua E. Budde, Marcelo C. Pasquini, Amy Moskop, Hairong Xu, Nausheen Ahmed, Cameron J. Turtle, Soyoung Kim, Michael L. Wang, Daniel Y. Lee, Ana Nunes, Swetha Kambhampati, Brent R. Logan, Daniel P. Dalton
article en
8 citations

Abstract

Brexucabtagene autoleucel (brexu-cel) is a chimeric antigen receptor T-cell therapy approved for relapsed/refractory mantle cell lymphoma (R/R MCL). Here, we report real-world effectiveness and safety outcomes of brexu-cel in a prospective study of patients with R/R MCL, including subgroups based on prior treatment with Bruton's tyrosine kinase inhibitor, bendamustine, or autologous hematopoietic cell transplant (auto-HCT) and number of prior therapy lines, using Center for International Blood and Marrow Transplant Research registry data. A total of 476 patients with R/R MCL who received brexu-cel between July 2020 and December 2022 were included in the analysis. With a median follow-up of 13.5 months, the overall response rate was 91% and complete response rate was 82%. One-year overall survival and progression-free survival rates were 76% and 63%, respectively. One-year cumulative incidence of nonrelapse mortality was 8%. Prior auto-HCT was associated with better duration of response within 6 months after infusion (hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.28-0.85) but greater risk of immune effector cell-associated neurotoxicity syndrome (odds ratio [OR], 1.66; 95% CI, 1.06-2.60). Prior bendamustine was associated with increased risk of prolonged thrombocytopenia (OR, 1.90; 95% CI, 1.13-3.21). In patients with 1 to 2 prior therapy lines, relapse or progression was less frequent compared with those with ≥3 prior lines (HR, 0.64; 95% CI, 0.42-1.00). Collectively, our results suggest that real-world outcomes with brexu-cel were consistent with those of the ZUMA-2 trial, regardless of prior therapy type or number of prior therapy lines.

Blood AdvancesVol. 9(20)
University of North Carolina at Chapel Hill (US), The University of Sydney (AU), City Of Hope National Medical Center (US), Cleveland Clinic (US), Memorial Sloan Kettering Cancer Center (US), The University of Texas MD Anderson Cancer Center (US), Medical College of Wisconsin (US), Jacksonville College (US), University of Vermont Medical Center (US), WinnMed (US), Moffitt Cancer Center (US), Nemours Children’s Clinic (US), Fred Hutch Cancer Center (US), The University of Kansas Cancer Center (US), City of Hope (US), Versiti Blood Center of Wisconsin (US), Gilead Sciences (Australia) (AU), Kite (United States) (US), Mayo Clinic in Florida (US), Nemours Children's Clinic (US), UNC Lineberger Comprehensive Cancer Center, Stanford University (US)
Gateway for Cancer Research, Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Astellas Pharma US, AstraZeneca, GlaxoSmithKline, Sanofi, Gilead Sciences, Alexion Pharmaceuticals, Spectrum Pharmaceuticals, Celgene, HistoGenetics, CSL Behring, Actinium Pharmaceuticals, Jazz Pharmaceuticals, Society for Immunotherapy of Cancer, Mallinckrodt Pharmaceuticals, Atara Biotherapeutics, CareDx, bluebird bio, Adaptive Biotechnologies, BeiGene, Incyte, Seagen, Kiadis Pharma, Astellas Pharma, Aptitude Health, Health Resources and Services Administration, Genentech, Kite Pharma, Pharmacyclics, Juno Therapeutics, Legend Biotech, National Heart, Lung, and Blood Institute, Office of Naval Research, National Cancer Institute, National Institute of Allergy and Infectious Diseases, Eurostars
Good health and well-being
Openalex Percentile: Top 2%
CAR-T cell therapy research
8.36
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.